Maini covers the Healthcare sector, focusing on stocks such as Tenax Therapeutics, Tectonic Therapeutic, and Liquidia Technologies. According to TipRanks, Maini has an average return of 28.6% and a 93.75% success rate on recommended stocks.
Liquidia Technologies has an analyst consensus of Strong Buy, with a price target consensus of $87.29.
Based on Liquidia Technologies’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $132.87 million and a net profit of $52.86 million. In comparison, last year the company earned a revenue of $3.12 million and had a GAAP net loss of $38.37 million
Based on the recent corporate insider activity of 123 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LQDA in relation to earlier this year. Earlier this month, Stephen Bloch, a Director at LQDA sold 200,000.00 shares for a total of $17,785,147.56.
Read More on LQDA:
